Home » Clinical Trials » Therapeutic Areas
Therapeutic Areas: Rheumatology | Musculoskeletal | Immunology | Family Medicine
Disease Category: Rheumatoid Arthritis
Location: United States, MD
Phase 3 Randomized, Double-Blind Study of the Efficacy and Safety of 2 Doses of JAK-3, Compared to Methotrexate Naive patients with Rheumatoid Arthritis
Do you have Rheumatoid arthritis? You may qualify to participate in a clinical research study.
JAK-3 inhibitors represent the first oral class of medication to have a demonstrable effect on a targeted component of the immune system. Seropositive rheumatoid arthritis patients are needed for this study. This double-blinded placebo controlled phase III trial is for a 2 year period, but does not limit patients to prior drug failures.
The Center for Rheumatology and Bone Research
2730 University Blvd West, Suite 306
Wheaton, MD 20902
Phone: 301 942-6610
Fax: 301 942-7833
If you would like to learn more about participating in this study, please send an email message using the form below.
DISCLAIMER: This site is run by CenterWatch, a publishing company that focuses on the
clinical trials industry. The information provided in this service is designed
to help patients find clinical trials that may be of interest to them, and to
help patients contact the centers conducting the research. CenterWatch is
neither promoting this research nor involved in conducting any of these